BACKGROUND: Inflammatory breast cancer (IBC) is associated with a poor prognosis and high risk of central nervous system (CNS) metastases. METHODS: We retrospectively reviewed stage III-IBC patients compared with noninflammatory invasive ductal carcinoma (NI-IDC) patients treated between January 1, 1984, and December 31, 2011, who began primary treatment within 1 year of diagnosis and had been followed up for at least 1 year before the development of CNS metastasis or death. Cumulative CNS metastasis incidence and post-CNS metastasis overall survival (OS) estimates were computed. Multivariable Cox proportional hazard models explored factors for post-CNS metastasis survival. RESULTS: A total of 2323 patients were identified (589-IBC/1734-NI-IDC). Eightyone IBC patients developed CNS metastasis, versus 154 NI-IDC patients. The 2-, 5-, and 10-year cumulative CNS metastasis incidence rates in IBC and NI-IDC were 9.8%, 15.8%, 17.4% and 6.5%, 10.1%, and 12.7%, respectively. This was significantly different between IBC and NI-IDC patients (P 5 .0037). Multicovariate competing risk regression models in IBC and NI-IDC patients showed no statistically significant associations with the risk of developing CNS metastasis, except neoadjuvant taxane use in NI-IDC patients (hazard ratio, 0.45; 95% confidence interval, 0.24-0.83; P 5 .011). The median follow-up was 7.2 years, and the median post-CNS metastasis OS was not significantly different between IBC (7.6 months) and NI-IDC (5.6 months) patients. One hundred ninety patients with CNS metastasis died. HER2-positive patients had better OS, with a median 14.1 versus 4.3 months (P < .0001). Age >50 years (P 5 .012) but not IBC status was a significant predictor of post-CNS metastasis survival. CONCLUSION: IBC patients demonstrated higher CNS metastasis incidence rates but OS following CNS metastases is similar in both groups. HER2 status and age may play prognostic roles. Cancer 2018;124:2299-305. V C 2018 American Cancer Society.
INTRODUCTION
Breast cancer is the second most common cause of CNS metastasis; 10% to 30% of all breast cancer patients will eventually develop CNS metastasis. 1 Although advances in breast cancer management have resulted in clinical outcome improvements, survival prolongation may lead to apparent increases in the incidence of CNS metastases. 2 In fact, the CNS can be the first recurrence site with an incidence rate of 2% to 14%. [3] [4] [5] Among concomitant extracranial and CNS metastasis, the incidence rate ranges from 10% to 30%. 6 Despite systemic cytotoxic and targeted therapies to control extracranial disease sites, improvement in the underlying CNS lesions may not be seen. 7 This may result from the presence of the blood-brain barrier and/or a different microenvironment compared with that of extracranial sites of metastasis. 8 IBC is a rare and highly aggressive form of breast cancer. It accounts for 1% to 2% of all invasive breast cancers and is associated with a high risk of recurrence, metastasis, and death. 4, 9 Despite aggressive multidisciplinary management, patients with IBC have a high risk of developing CNS metastases. 10, 11 In addition, when comparing all-stage 5-year survival, IBC patients have poorer survival when compared with noninflammatory breast cancer patients (40% vs 87%). 4, 12, 13 Development of CNS metastases usually portends a poor prognosis with a median survival of about 6 months or less. 14 Although surveillance guidelines do not recommend routine brain imaging at diagnosis or recurrence unless suspicious neurological symptoms are present, identifying high-risk populations such as patients with IBC may influence surveillance, personalized therapy, and prognostication. The main purpose of this retrospective study was to compile the largest cohort of IBC patients without CNS metastases in parallel with a noninflammatory, locally advanced breast cancer cohort to compare their CNS metastasis incidence rate and survival. We also sought to determine any associated clinicopathologic variables with prognostic significance for survival after development of CNS metastasis.
MATERIALS AND METHODS

Patient Population
The University of Texas MD Anderson Cancer Center (MDACC) Institutional Review Board approved this retrospective analysis with an informed consent waiver. Patient records and clinical information were anonymized and deidentified before analysis. We reviewed the Department of Breast Medical Oncology's tumor registry records for patients treated at MDACC between January 1, 1984, and December 31, 2011, who had stage III IDC. Included patients were required to have initiated primary treatment within 1 year of diagnosis and have follow-up for at least 1 year before the development of CNS metastasis or death. IBC was defined by standard American Joint Committee on Cancer criteria, which included history of rapid onset of breast erythema, edema, and/or peau d 'orange, with or without underlying palpable mass; duration of history <6 months; and pathological confirmation of invasive carcinoma from a core breast biopsy with or without dermal lymphatic involvement.
We used patient medical records to obtain clinicopathologic characteristics, including age at diagnosis, ethnicity, menopausal status, tumor grade, histopathology, estrogen/progesterone (ER/PR) receptor status, human epidermal growth factor receptor 2 (HER2) status, and lymphatic and vascular involvement. ER and PR status were determined by immunohistochemistry (IHC) and were considered positive if >10% of cells were stained for ER and/or PR. HER2 status was assessed by IHC or fluorescence in situ hybridization (FISH) and was considered amplified if >30% of cells were stained (IHC 31) or if the HER2/centromere enumerator probe ratio on FISH was 2.0. MDACC breast pathologists confirmed all findings. Treatment characteristics included adjuvant radiation, hormonal therapy, adjuvant/neoadjuvant chemotherapy, adjuvant/neoadjuvant anthracycline and taxane use, and definitive surgery (defined as either lumpectomy or mastectomy).
Methodology
Patients were divided into 2 groups: IBC or NI-IDC. The primary endpoint was cumulative incidence rate of CNS metastasis or death 1 year after diagnosis. The endpoint was the time to brain metastases development computed while treating death without brain metastases as a competing risk. CNS metastases were defined as intraparenchymal lesions only; patients with leptomeningeal disease were excluded. Importantly, we omitted patients that were censored, died, or had brain metastases within the first year. Those who were lost to follow-up were not censored from the data. Of the patients who developed CNS metastasis, we then analyzed their overall survival (OS) and clinicopathologic factors stratified by IBC or NI-IDC to explore any factors associated with survival.
Statistical Analysis
To quantify the risk of developing CNS metastasis, we used the cumulative incidence function because the usual Kaplan-Meier survival-based estimates are biased high due to patients dying without CNS metastasis being counted as simple censoring events rather than as competing risks. 15 To compare cumulative incidence functions, we used Gray's test. 16 To assess the effects of covariates on the cumulative incidence function, we used the univariate and multicovariate proportional hazards models of Fine and Gray. 17 For the multivariate competing risk regression model analysis, we first evaluated a model with all covariates of interest for each subgroup and then kept only those with P < .20 in the final multicovariate model for either subgroup. The Kaplan-Meier product limit method was used to estimate the survival outcomes of IBC and NI-IDC in those patients who developed CNS metastasis. In addition, a Cox proportional hazard regression analysis and covariate analysis was performed to analyze associations with post-CNS metastasis survival. All analyses were performed using SAS 9.3 and R version 2.15.3 (R Foundation for Statistical Computing) including the cmprsk package. P < .05 was considered statistically significant, and all tests were 2-sided.
RESULTS
Baseline Characteristics
A total of 2323 patients who were treated for stage III IDC between 1984 and 2011 were identified that fit the eligibility criteria. Table 1 summarizes the clinical, pathological, and treatment variables of the study population stratified by IBC or NI-IDC. We identified 589 patients with IBC and 1734 with NI-IDC. The median age at diagnosis was 50 years for both groups (range, 22 to 96 years). Compared with the IBC cohort, the NI-IDC cohort had more racial diversity, negative lymphatic and vascular invasion (60.3% vs 39.7% and 63.9% vs 48.4, respectively), lower grade, and more ER-and/or PR-positive tumors (63.8 vs 49.6%).
In terms of treatment, the IBC group received more neoadjuvant or adjuvant chemotherapy compared with the NI-IDC group (98% vs 87.6% and 48.9% vs 40.4%, respectively) and more neoadjuvant anthracycline (87.6% vs 79.2%). IBC patients were less likely to receive adjuvant hormonal therapy (35.5% vs 51%) and adjuvant radiation (77.9 vs 83.3%).
All other patient and clinical characteristics including age, menopausal status, HER2 status definitive surgery, anthracycline, and taxane use were similar between the 2 groups ( Table 1 ).
Development of CNS Metastasis
A total of 235 patients developed CNS metastasis, of whom 81 (13.6%) had IBC and 154 (8.9%) had NI-IDC. The 2-, 5-, and 10-year cumulative incidence rates of CNS metastasis in IBC and NI-IDC were 9.8%, 15.8%, and 17.4% and 6.5%, 10.1%, and 12.7%, respectively (Fig. 1 ). This occurrence rate was significantly different between IBC and NI-IDC patients (P 5 .0037). Supporting Table 1 presents the univariate competing risk regression model for IBC patients and shows that age, menopausal status, PR status, HER2 status, and adjuvant taxane use were significant for the development of CNS metastasis. However, multicovariate competing risk regression models showed no statistically significant associations (Supporting Table 2 ). In terms of NI-IDC patients, Supporting Table 4 ). Supporting Table 5 shows a summary of patients with CNS metastasis and their breast cancer subtype.
Post-CNS Metastasis OS
With a median follow-up for all patients of 7.2 years (range, 0 to 21 years), 190 of the 235 patients (81%) had died. Median post-CNS metastasis OS was not significantly different between IBC (7.6 months) and NI-IDC (5.6 months) patients (Fig. 2) . A combined group multivariate analysis for post-CNS metastasis survival showed that IBC status was not significant (HR, 0.89; 95% CI, 0.64-1.24; P 5 .49), but age (HR, 1.63; 95% CI, 1.18-2.24; P 5 .0028) and triple negative status (HR, 1.73; 95% CI, 1.23-2.44; P 5 .0016) were associated with worse survival (Table 2) . Other factors such as ethnicity (white vs not), grade (III vs I/II), lymphatic invasion, vascular invasion, menopause (post vs other), N stage, adjuvant hormonal therapy, any radiation (neoadjuvant vs adjuvant), and any taxane treatment were not significant predictors of post-CNS metastasis survival (data not shown).
To clarify the triple-negative status and its association with survival, we conducted a covariate analysis with HER2, hormone receptor status, and age that revealed that age (HR, 1.5; 95% CI, 1.1-2.2; P 5 .012) and HER2 status (HR, 0.4; 95% CI, 0.3-0.6; P < .0001) were associated with survival (Table 3) . We then analyzed median post-CNS metastasis survival based on HER2 and hormone receptor status. This analysis revealed that HER2 nonamplified/hormone receptor-negative (n 5 58) patients had a survival of 3.8 months; HER2 nonamplified/hormone receptor-positive (n 5 48) patients had a survival of 4.3 months; HER2 amplified/ hormone receptor-negative (n 5 39) patients had a survival of 11.6 months; and HER2 amplified/hormone receptor-positive (n 5 36) patients had a survival of 16.6 months (Table 3) . Based on HER2 status, the median post-CNS metastasis survival from the combined IBC and NI-IDC groups were 4.3 months in HER2 nonamplified patients (n 5 108) and 14.1 months in HER2 amplified patients (n 5 75) (Fig. 3) .
DISCUSSION
This retrospective review examined the CNS metastasis incidence rate in IBC compared with a high-risk cohort of locally advanced invasive ductal carcinoma patients and evaluated their post-CNS metastases survival. This study compiled one of the largest known cohorts of IBC patients to date. The overall development of CNS metastases in both cohorts compared favorably with previously reported data. Dawood et al, 11 for example, analyzed the incidence of brain metastases in stage III/IV IBC patients and reported an overall occurrence of 13.2%. Similarly, Gonzalez-Angulo et al 10 analyzed the development of CNS metastases in a high-risk locally advanced breast cancer population and found the overall incidence to be 8%. In our present study, we attempted to exclude patients who may have had CNS metastases at initial presentation and found an overall incidence rate of 13.6% in IBC and 8.9% in NI-IDC patients (P 5 .0037). We were not able to identify any specific patient or tumor characteristics in our multivariate analysis that were associated with the development of CNS metastases in either cohort except for neoadjuvant taxane use, which seemed to reduce this development in NI-IDC patients.
This observation may be partly explained by the findings reported in NSABP-18 and NSABP-27. 18, 19 NSABP-18 examined whether neoadjuvant chemotherapy with doxorubicin and cyclophosphamide (AC) improved breast cancer disease-free survival (DFS) and overall survival (OS) compared to adjuvant administration. NSABP-27 examined the added effect of docetaxel in the pre-and postoperative setting. Both studies showed no difference in DFS and OS, but did show that preoperative docetaxel added to AC increased the proportion of patients having pathological complete remission (26% vs 13%; P < .0001). Furthermore, those patients who achieved pathological complete remission did have improved DFS and OS. 20 No study has specifically evaluated the role and timing of chemotherapy in developing CNS metastases, however, neoadjuvant chemotherapy does lead to decrease tumor size, increased rates of breastconserving treatment, and increased rates of negative axillary lymph nodes. 21 Thus, our finding may relate to the theoretical advantage that neoadjuvant taxane use allows for early treatment of micro-metastatic disease, and taxane use may have more potency in the neoadjuvant setting. This effect was not seen in the IBC cohort, which may attest to IBC's different, more aggressive disease biology and reduced chemotherapeutic efficacy.
Interestingly, although the literature has supported increased CNS metastasis risk for patients with triplenegative and HER2-amplified breast cancer over hormone receptor-positive breast cancer, these prognostic features were not shown to be significant in our IBC cohort. It is our belief that the underlying, unfavorable biology of IBC overcomes the contribution of molecular breast cancer subtype, a finding our group has reported previously. 4, 22 Furthermore, if we consider CNS metastasis a negative prognostic feature, this observation seems to go against data recently published by Li et al, 23 who showed that breast cancer molecular subtype did, in fact, strongly influence OS and breast cancer-specific mortality. It should be noted, however, that the patient population used in that study came from SEER data from 2010-2013, which was a much different era of therapy, especially for HER21 disease.
IBC is an aggressive form of breast cancer that is associated with poorer outcomes compared with non-IBC tumors. However, when evaluating post CNS metastasis survival for both cohorts, we demonstrated that survival was similar between the 2 groups (IBC, 7.6 months; NI-IDC, 5.6 months), and these data are comparable to those reported historically. 4, 10, 12 Our combined group multivariate analysis for post-CNS metastases survival showed that IBC was not significant (HR, 0.89; 95% CI, 0.64-1.24; P 5 .49) suggesting that the poor survival of patients with CNS metastases is independent of IBC or NI-IBC classification. When examining other prognostic factors, we show that age >50 years portends a worse survival, whereas HER2 status is associated with an increase in survival. It has been shown previously that age independently affects CNS metastases incidence and survival. Young age (usually <50 years) is associated with a higher rate of CNS metastases development, whereas older age correlates with worse OS. 24, 25 In addition, several studies show that amplified HER2 status increases a patient's risk for CNS metastases. However, it has been suggested that despite this risk, there is an improvement in survival that may be related to anti-HER2 therapy such as trastuzumab. 26, 27 Given that our patient population spanned from 1984 to 2011, some patients did not have HER2 testing and/or did not receive anti-HER2 therapy. Although our findings, which demonstrate significantly prolonged survival in patients with amplified versus nonamplified HER2 status (14.1 months vs 4.3 months) are consistent with the reported (albeit limited) literature, we acknowledge that improved anti-HER2 therapies with trastuzumab and others may be driving the improved outcome for HER2-amplified patients.
Our study has several limitations. First, the analysis was retrospective, which can result in selection and information retrieval biases. Second, one could argue that the broad study timeframe limits our analysis considering the improved treatment options for breast cancer, especially regarding anti-HER2 therapies and our ability to detect distant metastases. It may be, for example, that the HER2-amplified patients have even better survival than demonstrated in our patient cohort, given that patients diagnosed in the first decade of this study would have received HER2-directed therapies. Finally, we report on patients from a single academic center. Our results may not be applicable to patients treated elsewhere, where differences in surgical or radiotherapy expertise, and availably of systemic therapies may affect treatment strategies and patient outcomes.
In conclusion, these results indicate that IBC is associated with a higher incidence of CNS metastases; however, once CNS metastases develop, survival is not affected by IBC status. In fact, in terms of therapy, HER2 status plays a significant role in the management of these patients. In addition, our observations suggest that IBC patients may be an ideal study cohort for CNS metastases screening programs which may allow for earlier detection and intervention. 
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